Microsoft word - lani phase iii clinical trials in asia prove successful.doc
LANI Phase III clinical trials in Asia prove successful
Biota Holdings Limited (ASX:BTA) today announced successful results from the Asian
Phase III clinical trials of CS-8958, its second generation influenza treatment. CS-8958
now has been assigned the new name of ‘laninamivir’ by the World Health Organization under its International Non-proprietary Names (INN) drug identification system. Laninamivir is a long acting neuraminidase inhibitor (LANI) and is co-owned with
Daiichi Sankyo. In the Phase III trial in adults, a single inhaled dose of laninamivir was shown to be
as effective as oseltamivir (Tamiflu) administered orally twice daily for 5 days (total of 10 doses). A parallel Phase II/III trial of CS-8958 in paediatric patients also met the
primary and secondary endpoints compared to oseltamivir. “The success of the multifaceted Phase III trials in Asia is significant. Laninamivir offers
a new therapeutic agent in the treatment of influenza with particular advantages for
” said Peter Cook, Biota's Managing Director. Trial Results
The Phase III study was conducted by Daiichi Sankyo in Japan, Taiwan, Hong Kong and
Korea and enrolled approximately 1,000 adult patients who had confirmed, naturally
acquired influenza A or B. Patients in the trial received either 20mg or 40mg of laninamivir as a single inhaled dose or 75mg of oseltamivir twice daily for five days. Participants in
the trial were distributed equally across three treatment groups. The primary end point of the trial was time to symptom resolution, while the secondary end point was time for
body temperature to return to normal. Both doses of laninamivir were as effective as oseltamivir and were well tolerated. The parallel Phase II/III double-blind paediatric study of laninamivir was conducted
in Japan in approximately 180 children aged at nine years or younger. This study also compared the safety and efficacy of 20mg or 40mg of laninamivir as a single inhaled
dose with oseltamivir, administered at a dose of 2mg/kg twice daily for five days. Approximately 60 children were enrolled in each treatment arm of the study. The primary
and secondary end points used in this trial were the same as those used in the adult study. Both doses of laninamivir were equivalent to oseltamivir and were well tolerated by
paediatric patients. There was also a trend towards the single inhaled doses of 20mg
or 40mg of laninamivir showing a faster time to the alleviation of influenza illness than
oseltamivir dosed at 2mg/kg twice daily for five days.
Pre-clinical tests have shown laninamivir to be effective against influenza A & B virus
as well as against the H5N1 avian influenza virus. A recent paper in the journal Nature
published by University of Tokyo virologist Yoshihiro Kawaoka et al indicated that
laninamivir is also active against the new swine originated influenza A H1N1 virus.
Daiichi Sankyo has secured the rights to manufacture and market laninamivir in Japan
and funded the Japanese trials. Daiichi Sankyo is seeking approval from the Japanese
regulatory authority to market laninamivir in Japan, with submission anticipated by March 2010. A clinical study for prophylaxis of influenza is expected to commence in Japan in late 2009. Biota will receive an undisclosed royalty on sales and a number of fixed sum payments on the achievement of certain sales milestones. Biota will continue to advance the clinical development program required to support registration in North America and Europe. The US National Institutes of Health has to date
committed a total of US$5.6 million to support the western clinical development program. A licensing partner is now being sought for all markets outside Japan, including the US.
Under the Commercialisation and Licence Agreement between Biota and Daiichi Sankyo, the parties will share commercial returns from licensing outside Japan. A separate announcement will be made by Daiichi Sankyo in Japan today.
About LANI’s (Long-Acting Neuraminidase Inhibitors)
Current neuraminidase inhibitors for influenza require daily or more frequent dosing.
The ability to dose patients on a weekly, or even less frequent, basis offers numerous benefits. Firstly, any stockpile of weekly-dosing drug will last longer and protect more
people, in the case of an influenza pandemic. Additionally, a weekly dose may improve patient compliance over a more frequent regime.
About Daiichi Sankyo
A global pharmaceutical innovator, Daiichi Sankyo Co., Ltd., was established in 2005
through the merger of two leading Japanese pharmaceutical companies. Daiichi Sankyo
discovered laninamivir and has a key partnership with Biota for the development of the product.
*Further information, visit www.daiichisankyo.com
Biota is a leading anti-infective drug development company based in Melbourne Australia,
with key expertise in respiratory diseases, particularly influenza. Biota developed the first-
in-class neuraminidase inhibitor, zanamivir, subsequently marketed by GlaxoSmithKline as Relenza. Biota research breakthroughs have included novel nucleoside analogues designed
to treat hepatitis C virus (HCV) infections, licensed to Boehringer Ingelheim, and a series of candidate drugs aimed at treatment of respiratory syncytial virus (RSV) disease. Biota
has clinical trials underway with its lead compound for human rhinovirus (HRV) infection in patients with compromised respiration or immune systems. In addition, Biota has a key partnership with Daiichi Sankyo for the development of second generation influenza
Relenza™ is a registered trademark of the GlaxoSmithKline group of companies. *Further information available at www.biota.com.au
Investor / Analyst Enquiries
Biota Holdings Limited
IQWiG Reports – Commission No. A05-05C Glinides in the treatment of diabetes mellitus Executive Summary 1Translation of the executive summary of the final report “Glinide zur Behandlung des Diabetes mellitus Typ 2” (Version 1.0; Status: 06.04.2009). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original te
Een gewichtsverlies van 5 tot 10 procent is mogelijk wanneer mensen kiezen voor een energiebeperkt dieet en meer lichamelijke activiteit. Om het gewichtsverlies te behouden is gedragsverandering noodzakelijk. Wanneer ter ondersteuning van de gedragsverandering ook medicatie wordt gebruikt, zijn mensen beter in staat de gedragsverandering te realiseren en zo wordt meer gewichtsve